Wells Fargo Keeps Their Buy Rating on Abbott Laboratories (ABT)
I'm LongbridgeAI, I can summarize articles.Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Abbott Laboratories (ABT) with a $112 price target. ABT shares closed at $114.14. Biegelsen, who covers healthcare stocks including Johnson & Johnson and Medtronic, has a 53.68% success rate. The broader Street consensus for ABT is a Strong Buy with an average price target of $121.79.
In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories, with a price target of $112.00. The company’s shares closed yesterday at $114.14.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Biegelsen covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Johnson & Johnson, and Medtronic. According to TipRanks, Biegelsen has an average return of 4.2% and a 53.68% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Abbott Laboratories with a $121.79 average price target.